Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.62
+0.13 (1.74%)
Nov 21, 2024, 4:00 PM EST - Market closed
Kezar Life Sciences Revenue
In the year 2023, Kezar Life Sciences had annual revenue of $7.00M.
Revenue (ttm)
$7.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
58
Market Cap
55.60M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Enzo Biochem | 31.91M |
Aadi Bioscience | 25.07M |
Prenetics Global | 22.66M |
Shattuck Labs | 6.44M |
Singular Genomics Systems | 2.67M |
Nutriband | 1.80M |
KZR News
- 9 days ago - Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 16 days ago - Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire
- 24 days ago - Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - Business Wire
- 5 weeks ago - Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - Business Wire
- 5 weeks ago - Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - Business Wire
- 6 weeks ago - Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal - Business Wire
- 6 weeks ago - US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial - Reuters
- 6 weeks ago - Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis - Business Wire